

Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

# Longevity Economy strategy Omicron variant and expectations on interest rates rises impacted Longevity Economy businesses

- Global equity markets fell amidst new Covid-19 variant discovery and higher expectations for interest rates increase
- Heightened uncertainties are creating new opportunities for the strategy
- Focus remains on long-term changes brought about by ageing populations

**Peter Hughes**  
**Portfolio Manager, Longevity Economy Strategy**

## What's happening?

Global equity markets fell in November as the discovery of a new coronavirus variant in South Africa spurred multiple countries to re-introduce some social distancing measures and travel restrictions causing markets to react negatively. Furthermore, the lower trading volumes experienced around the Thanksgiving Holiday in the US exacerbated the impact of the market uncertainty.

Additionally, comments from the US Federal Reserve Chairman, Jerome Powell, suggest that US interest rate rises could occur more sharply than the market expected. This led to increases in US government bond yields and a sell-off in riskier assets, such as growth equities.

The combination of increased COVID-19 uncertainty and higher expectations for interest rate increases created a very challenging environment for stocks exposed to the longevity economy. Higher COVID-19 uncertainty caused broad volatility, but it was particularly apparent in stocks of travel and leisure companies. Expectations of higher interest rate increases caused volatility in many growth equities, particularly for medtech and biotech stocks. Moreover, this challenging environment contributed to volatility in some financials exposed to market levels and trading volumes, such as asset and private wealth managers.

## Portfolio positioning and performance

All four themes of the longevity economy (wellness, silver spending, senior care and treatment) experienced declines in November as no theme was immune to the market volatility discussed above. The longevity economy strategy underperformed the broader equity market (MSCI All Country World) during the month.

There are several reasons for the strategy's underperformance. Firstly, the strategy's high exposure to growth stocks, many of which experienced larger declines than the market average as investors priced in larger discount weights for future growth due to higher expected interest rates. Secondly, the strategy has significant exposures to stocks perceived to be more negatively impacted by a resurgence in COVID-19, such as the travel and leisure sector and surgical equipment providers.

Over the long-term we believe the global economy will continue to normalise and the themes that were driving the longevity economy prior to the emergence of COVID-19 are likely to reassert themselves on stock performance. So, we continue to position the strategy to benefit from this long-term trend. Given the recent volatility we are also finding significant opportunities to invest at very attractive stock prices, including highly cash generative businesses that we believe can mitigate some of the exposure to the risk of higher interest rates experienced by growth companies that are net investors of cash.

## Outlook

As we have previously highlighted, it has become more difficult for investors to forecast near-term financial results. The emergence of the Omicron COVID-19 variant has unsettled investors because, at time of writing, there are many unknowns about the impact of the mutations in Omicron's genetic code will have on transmissibility and the ability of existing vaccines and treatments to mitigate the severity of infection. It will take several weeks to answer these questions and in the meantime a lot of the debate around the Omicron variant will be highly speculative.

The consensus is that COVID-19 highly likely to become endemic and, if so, healthcare systems will need to adapt to the virus's continued presence while allowing economies to normalise. Therefore, taking a long-term perspective, we see the current volatility as an opportunity to increase exposure to stocks we believe have the best long-term prospects. Although we believe significant volatility could persist for some time.

The longevity economy strategy continues to be positioned to benefit from the long-term demographic change in the global population and the impact we believe this will have on consumption trends. With the rate of growth in persons over 65 years' old accelerating in Western economies over the next few years we believe this positions the strategy for long-term secular growth. However, it also exposes the strategy to some sectors that rely on healthcare systems to be capable of managing spikes in COVID-19 while economic activity largely continues unrestricted. As such, volatility in the strategy's performance could continue if investor's doubt this balance can be achieved.

**No assurance can be given that the Longevity Economy Strategy will be successful. Investors can lose some or all of their capital invested. The Longevity Economy Strategy is subject to risks including: Equity; Currency; Global Investments; Emerging markets; Investments in small capitalisation universe and Investment in specific asset classes.**

El presente documento y cualquier información y/o datos financieros reseñados en el mismo no suponen invitación o recomendación de adquisición o inversión, ni deben constituir la base para la toma de decisiones inversoras ni de garantía de rentabilidad futura de inversiones financieras y, en ningún caso, está dirigido a clientes minoristas y/o inversores finales. La información contenida en el mismo está destinada a clientes profesionales y contrapartes elegibles tal y como son definidos en tanto en los artículos 205 y 207 del Texto Refundido de la Ley del Mercado de Valores como en las normas MiFID (Directiva sobre Mercados de Instrumentos Financieros) 2004/39/CE, presumiéndose, por tanto, la experiencia, conocimientos y cualificación necesarios para tomar sus propias decisiones de inversión y valorar correctamente sus riesgos y el de sus clientes. Dicha información y datos tienen una finalidad meramente informativa y se recomienda tener un conocimiento más detallado a través de los documentos y folletos inscritos en los organismos nacionales e internacionales de regulación especialmente la toma en consideración y conocimiento del Documento de Datos Fundamentales para el Inversor (DFI). El receptor de esta información debe tener presente que la evolución de las variables económicas y los valores de los mercados financieros pueden cambiar significativamente y ser diferentes a los análisis e indicaciones que figuran en este documento. Los inversores deben tener en cuenta que el mercado financiero es fluctuante y que está sujeto a variaciones y que los tipos de cambio pueden sufrir oscilaciones que incidan directamente en la rentabilidad de las inversiones, tanto al alza como a la baja. No debe tomarse como referencia la rentabilidad pasada del producto pues no implica que se comporte de igual forma en el futuro. Para una mayor información y especialmente para el conocimiento de la disponibilidad de los productos se recomienda visitar las páginas web, [www.axa-im.com](http://www.axa-im.com) y [www.axa-im.es](http://www.axa-im.es). Les invitamos a verificar con la sociedad de gestión o directamente en nuestra página web, [www.axa-im.com](http://www.axa-im.com), la lista de países en los que se comercializa el fondo.

AXA INVESTMENT MANAGERS no asume responsabilidad alguna por cualquier acto u omisión derivada del uso de la información facilitada, declinando toda responsabilidad por el uso incorrecto o inadecuado del presente documento.

AXA INVESTMENT MANAGERS PARIS, S.A., SUCURSAL EN ESPAÑA, tiene su domicilio social en Madrid, Paseo de la Castellana núm. 93, 6ª planta, se encuentra inscrita en el Registro Mercantil de Madrid, hoja M-727252, tomo 41006, folio 1; y se encuentra registrada en la CNMV bajo el número 38 como Sociedad gestora UCITS del espacio económico europeo con sucursal.

AXA FUNDS MANAGEMENT, es una sociedad anónima constituida conforme a la legislación vigente en Luxemburgo, con número de Registro en Luxemburgo B 32.223RC, y con domicilio social situado en el nº 49, Avenue J.F. Kennedy L-1885 Luxemburgo.

AXA ROSENBERG MANAGEMENT IRELAND LIMITED es una sociedad de responsabilidad limitada constituida y regulada por las leyes de Irlanda, con domicilio social en 78 Sir John Rogerson's Quay Dublín 2, regulada por el Banco Central de Irlanda y registrada en dicho Estado con el número 310308.

Los subfondos de AXA WORLD FUNDS, SICAV de derecho luxemburgués armonizada domiciliada en 49 Avenue J.F. Kennedy L-1855 (Luxemburgo), registrada en la CSSF y en el Registro Mercantil de Luxemburgo bajo el número B-63.116 están inscritos en la CNMV con el número 239 (\*verificar en CNMV las clases registradas).

Los subfondos de AXA ROSENBERG EQUITY ALPHA TRUST, fondo de derecho irlandés armonizado, domiciliado en Dublín 1 (Irlanda) Guaid House Guaid Street registrado en la Ireland Financial Market Authority (IFMA) bajo el número 310308 están inscritos en la CNMV con el número 294 (\*verificar en CNMV las clases registradas).

Los subfondos de AXA IM FIXED INCOME INVESTMENT STRATEGIES, Fondo de Inversión de derecho luxemburgués armonizado, domiciliado en 49 Avenue J.F. Kennedy L-1855 (Luxemburgo), autorizado y registrado en la Commission de Surveillance du Secteur Financier CSSF bajo el número 3692 están inscritos en la CNMV con el número 867 (\*verificar en CNMV las clases registradas).